Study of fixed dose combination for the management of cardiovascular diseases
An Epidemic of Cardiovascular disease(CVD) is a predicted in the Indian subcontinent as a result of change in demographics and lifestyle and poor childhood nutrition impacting on disease in adult life. Lack of facilities for diagnosis and treatment of CVD and the cost of treatment mean that large sections of the Indian populations have poor access to both prevention and treatment. One cost effective approach, which could achieve substantial benefits within a few years, is provision of combined Cardiovascular(CV) medication to those at highest risk. The study was multicentre prospective open labeled single armed 12 week study. This includes Adults Male or Female age 18-75 years. Patients with at least one risk factor for cardiovascular disease namely Hypertension ≥ 139/89 mm of Hg and ≤ 180/110 mm of Hg according to JNC-VII guidelines and lipid profile LDL-C ≥ 130 mg/dl or LDL-C > 100 mg/ dl with CAD Equivalents or patient with coronary artery disease or high cardiovascular risk factors. At the screening visits. the total number of patients successfully completed the study were 27 as per inclusion criteria. The safety of combination pill on Moderate & Severe Hypertensive patients laboratory investigations show there is no increase in the SGOT, SGPT, Serum Creatinine, &Serum Electrolyte levels. so the combination pill consider as safe. The combination pill show higher safety.
Full Text Attachment